A detailed history of Lmr Partners LLP transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Lmr Partners LLP holds 30,000 shares of FULC stock, worth $260,100. This represents 0.0% of its overall portfolio holdings.

Number of Shares
30,000
Previous 50,000 40.0%
Holding current value
$260,100
Previous $344,000 24.13%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

SELL
$6.34 - $8.84 $126,800 - $176,800
-20,000 Reduced 40.0%
30,000 $261,000
Q2 2025

Aug 14, 2025

BUY
$2.51 - $7.38 $125,499 - $369,000
50,000 New
50,000 $344,000
Q4 2024

Feb 14, 2025

BUY
$2.97 - $4.84 $334,125 - $544,500
112,500 New
112,500 $528,000
Q1 2024

May 15, 2024

BUY
$6.7 - $12.0 $117,511 - $210,468
17,539 New
17,539 $165,000
Q4 2021

Feb 14, 2022

SELL
$14.0 - $28.44 $420,000 - $853,200
-30,000 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$7.28 - $30.97 $218,400 - $929,100
30,000 New
30,000 $846,000

Others Institutions Holding FULC

About Fulcrum Therapeutics, Inc.


  • Ticker FULC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,038,900
  • Market Cap $451M
  • Description
  • Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...
More about FULC
Track This Portfolio

Track Lmr Partners LLP Portfolio

Follow Lmr Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Lmr Partners LLP with notifications on news.